ACTA MEDICINAE 11/2014 Kompletní literatura Farmakologická léčba

ACTA MEDICINAE 11/2014
Farmakologická léčba
Kompletní literatura
2
Moderní protinádorová léčba – individualizovaná terapie, bioindikátory efektu a toxicita terapie,
nová léčiva
2
Systémová léčba zhoubných nádorů ledvin a novinky v roce 2014
2
Kolorektální karcinom: strategie pro včasnou diagnostiku
3
Individualizace adjuvantní/neoadjuvantní terapie nádorů prsu
3
Nintedanib, trojitý inhibitor angiokináz
3
Pleurální výpotek u pacientů s chronickou myeloidní leukemií léčených dasatinibem
4
Troponiny jako bioindikátory určitých typů kardiotoxicity léčiv
4
Glukokortikoidy šetřící léčba u systémového lupus erythematodes – zaměřeno na belimumab
5
Mirabegron: nové možnosti terapie hyperaktivního močového měchýře
MUDr. Denisa Vitásková | prof. MUDr. Bohuslav Melichar, Ph.D. Onkologická klinika, LF Univerzity Palackého a FN Olomouc
doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha
doc. MUDr. Bohumil Seifert, Ph.D. Ústav všeobecného lékařství 1. lékařské fakulty UK v Praze
MUDr. Adam Paulík | prof. MUDr. Stanislav Filip, Ph.D., DrSc. Klinika onkologie a radioterapie FN Hradec Králové
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol
MUDr. Hana Klamová, CSc. Ústav hematologie a krevní transfuze Praha
doc. MUDr. Michaela Adamcová, Ph.D. Ústav fyziologie, LF v Hradci Králové, Univerzita Karlova v Praze
MUDr. Hana Ciferská, Ph.D. Revmatologický ústav a Revmatologická klinika 1. LF UK a VFN, Praha
MUDr. Jan Vachek Klinika nefrologie VFN a 1. LF UK, Praha
MUDr. Roman Staněk Urologické oddělení Slezské nemocnice Opava
5Metoprolol
prof. MUDr. Jan Bultas, CSc. Farmakologický ústav 3. LF UK Praha
6
AMESOS – fixní kombinace lisinoprilu a amlodipinu v léčbě hypertenze
6
Farmakologická léčba obezity a diabetu
7
Praktické využití fixní kombinace perindopril/indapamid u nemocného s metabolickým syndromem
7
Personalizovaná léčba deprese
7
Individualizace farmakologické léčby v psychiatrii – zaostřeno na schizofrenii
8
Dlouhodobá účinnost glatiramer acetátu v podmínkách klinické praxe
8
Nové trendy ve vakcinologii
8
Avanafil – nová možnost volby v léčbě erektilní dysfunkce
MUDr. Jiří Slíva, MD., Ph.D. Ústavy farmakologie 2. a 3. LF UK Praha
prof. MUDr. Martin Haluzík, DrSc. III. interní klinika 1. LF UK a VFN, Praha
doc. MUDr. Jitka Seidlerová, Ph.D. Lékařská fakulta v Plzni, Univerzita Karlova v Praze, Biomedicínské centrum, Lékařská fakulta
v Plzni, Univerzita Karlova v Praze, Plzeň
prof. MUDr. Jiří Raboch, DrSc. Psychiatrická klinika 1. LF UK a VFN
prof. MUDr. Eva Češková, CSc. CEITEC – MU, Psychiatrická klinika FN Brno, Katedra interních oborů LF Ostravské univerzity
v Ostravě, Oddělení psychiatrické FN Ostrava
prof. MUDr. Ladislav Hosák, Ph.D. Psychiatrická klinika LF UK a FN Hradec Králové
MUDr. Jiří Slíva, MD., Ph.D. Ústavy farmakologie 2. a 3. LF UK Praha
MUDr. Veronika Horáková Ústav imunologie 2. LF a FN v Motole, Praha
MUDr. Lukáš Bittner, FEBU, FECSM Urologická klinika 3. LF UK a FNKV
Moderní protinádorová léčba – individualizovaná terapie,
bioindikátory efektu a toxicita terapie, nová léčiva
MUDr. Denisa Vitásková | prof. MUDr. Bohuslav Melichar, Ph.D.
Onkologická klinika, LF Univerzity Palackého a FN Olomouc
1 Adam, Z. – Vorlíček, J. – Vaníček, J., et al.: Diagnostické a léčebné postupy u maligních chorob. II. aktualizované a doplněné vydání. Grada,
Praha, 2004.
2 Adams, J. – Palombella, V. J. – Sausville, E. A., et al.: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer
Res, 1999, 59, s. 2615–2622.
3 Baselga, R.: Anti-EGFR therapy: A new targeted approach to cancer
treatment. Oncology Biotherapeutics, 2002, 2, s. 1–36.
4 Bianco, R. – Daniele, G. – Ciardiello, F.: Monoclonal antibodies targeting the epidermal growth factor receptor. Curr Drug Targets, 2005,
6, s. 275–287.
5 Dunn, G. P. – Old, L. J. – Schreiber, R. D.: The immunobiology of
cancer immunosurveillance and immunoediting. Immunity, 2004,
21, s. 137–148.
6 Klener, P. – Klener, P. jr.: Nová protinádorová léčiva a léčebné strategie
v onkologii. Grada, Praha, 2009.
7 Pardanani, A. – Tefferi, A.: Imatinib targets other then bcr/abl
and thair clinical relevance in myeloid disorders. Blood, 2004, 104,
s. 1931–1939.
8 Stern, M. – Hermann, R.: Overview of monoclonal antibodies in
cancer therapy: present and promise. Crit Rev Oncol Hematol, 2005,
54, s. 11–29.
9 Stewart, T. J. – Abrams, S. I.: How tumors escape mass destruction.
Oncogene, 2008, 27, s. 5894–5903.
10 Tibes, R. – Trent, J. – Kurzrock, R.: Tyrosine kinase inhibitors and the
dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol,
2005, 45, s. 357–384.
11 Vanneman, M. – Dranoff, G.: Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer, 2012, 12,
s. 237–251.
Systémová léčba zhoubných nádorů ledvin a novinky
v roce 2014
doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha
1 Novotvary 2007 ČR. ÚZIS ČR, 2010, www.svod.cz.
2 Hes, O. – Hora, M. – Michal, M.: Nová klasifikace nádorů ledvin dle
WHO 2004 – komentovaný přehled. Urol Listy, 2004, 3, s. 40–44.
3 Motzer, R. J. – Bacik, J. – Mazumdar, M.: Prognostic factors for survival
of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res, 2004, 10, s. 6302–6303.
4 Negrier, S., et al.: Recombinant human interleukin-2, recombinant
human interferon alfa-2a, or both in metastatic renal-cell carcinoma.
N Engl J Med, 1998, 338, s. 1273–1278.
5 Negrier, S. – Perol, D. – Ravaud, A., et al.: Medroxyprogesterone, interferon alfa-2a, interleukin 2 or combination of both cytokines in
patients with metastatic renal carcinoma of intermediate prognosis.
Cancer, 2007, 110, s. 2448–2457.
6 Kaelin, W. G.: Molecular basis of the VHL hereditary cancer syndrome.
Nat Rev Cancer, 2002, 2, s. 673–682.
7 Melichar, B. – Procházková-Študentová, H. – Vitásková, D., et al.: Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial. Expert Rev Anticancer Ther, 2012, 12, s. 1253–1261.
8 Escudier, B., et al., for the TARGET Study Group: Sorafenib in advanced
clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356, s. 125–134.
9 Motzer, R. J. – Hutson, T. E. – Tomczak, P., et al.: Overall survival and
updated results for sunitinib compared with interferon (IFN)-alfa in
patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol,
2009, 27, s. 3584–3590.
10 Sternberg, C. N. – Davis, I. D. – Kardiak, J., et al.: Pazopanib in locally
advanced or metastatic renal cell carcinoma: Results of a randomized
phase III trial. J Clin Oncol, 2010, 28, s. 1061–1068.
11 Motzer, R. J. – Hutson, T. E. – Cella, D., et al.: Pazopanib versus sunitinib
in metastatic renal-cell carcinoma. N Engl J Med, 2013, 369, s. 722–731,
doi: 10.1056/NEJMoa1303989.
12 Escudier, B. – Porta, C. – Bono, P., et al.: Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma:
PISCES Study. J Clin Oncol, 2014, 10, 32, s. 1412–1418, doi: 10.1200/
JCO.2013.50.8267, Epub 31. 3. 2014.
13 Rini, B. I. – Escudier, B. – Tomczak, P., et al.: Comparative effectiveness
of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS):
a randomised phase 3 trial. Lancet, 2011, 378, s. 1931–1939.
14 Hudes, G., et al., for the Global ARCC Trial: Temsirolimus, interferon-alpha, or both for advanced renal-cell carcinoma. N Engl J Med, 2007,
356, s. 2271–2281.
15 Motzer, R. – Escudier, B. – Oudard, S., et al.: Efficacy of everolimus in
advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 2008, 372, s. 449–456.
16 Büchler. T. – Klapka, R. – Melichar, B., et al.: Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from
the Czech registry. Ann Oncol, 2012, 23, s. 395–401, Epub 2. 5. 2011.
17 Iacovelli, R. – Cartenì, G. – Sternberg, C. N., et al.: Clinical outcomes
in patients receiving three lines of targeted therapy for metastatic
renal cell carcinoma: results from a large patient cohort. Eur J Cancer,
2013, 49, s. 2134–2142, doi: 10.1016/j.ejca.2013.02.032, Epub 18. 5.
2013.
18 Motzer, R. J. – Porta, C. – Vogelzang, N. J., et al.: Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic
renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol, 2014, 15, s. 286–296, doi: 10.1016/S1470-2045(14)70030-0,
Epub 17. 2. 2014.
19 Bhojani, N. – Jeldres, C. – Petard, J. J., et al.: Toxicities associated with
the administration of sorafenib, sunitinib, and temsirolimus and their
management in patients with metastatic renal cell carcinoma. Eur
Urol, 2008, 53, s. 917–930.
20 Morse, M. – McDermott, D. F. – Daniels, G. A., et al.: High-dose (HD)
IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and
partial response (PR). J Clin Oncol, 32, 5s, 2014 (dopl.; abstrakt 4523).
21 Motzer, R. J. – Rini, B. I. – McDermott, D. F., et al.: Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. J Clin Oncol, 2014, 32, 5s (dopl.; abstrakt 5009).
22 Choueiri, T. K. – Fishman, M. N. – Escudier, B. J., et al.: Immunomodulatory activity of nivolumab in previously treated and untreated
metastatic renal cell carcinoma (mRCC): Biomarker-based results from
a randomized clinical trial. J Clin Oncol, 2014, 32, 5s (dopl.; abstrakt
5012).
23 Hammers, H. J. – Plimack, E. R. – Infante, J. R., et al.: Phase I study of
nivolumab in combination with ipilimumab in metastatic renal cell
carcinoma (mRCC). J Clin Oncol, 2014, 32, 5s (dopl.; abstrakt 4504).
24 Amin, A. – Plimack, E. R. – Infante, J. R., et al.: Nivolumab (anti-PD-1;
BMS-936558, ONO-4538) in combination with sunitinib or pazopanib
in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin
Oncol, 2014, 32, 5s (dopl.; abstrakt 5010).
25 Amin, A. – Dudek, A. Z. – Logan, T. F., et al.: Long-term survival in
unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib. J Clin Oncol, 2014,
32, 5s (dopl.; abstrakt 4524).
26 Escudier, B. J. – Koscielny, S. – Lopatin, M., et al.: Validation of a 16-gene signature for prediction of recurrence after nephrectomy in
stage I–III clear cell renal cell carcinoma (ccRCC). J Clin Oncol, 2014,
32, 5s (dopl.; abstrakt 4502).
27 Johnson, T. – Xu, Ch. – Choueiri, T. K., et al.: Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or
sunitinib-treated patients with renal cell carcinoma (RCC). J Clin Oncol, 2014, 32, 5s (dopl.; abstrakt 4503).
28 Rini, B. I. – Dorff, T. B. – Elson, P., et al.: A prospective observational
study of metastatic renal cell carcinoma (mRCC) prior to initiation of
systemic therapy. J Clin Oncol, 2014, 32, 5s (dopl.; abstrakt 4520).
29 Mittal, K. – Derosa, L. – Albiges, L., et al.: Outcomes of treatment
cessation in select metastatic renal cell carcinoma (mRCC) patients.
J Clin Oncol, 2014, 32, 5s (dopl.; abstrakt 4521).
30 Alvarez, A. L. – Plimack, E. R. – Dreicer, R., et al.: A phase II study of
pazopanib (P) in patients (Pts) with localized renal cell carcinoma
(RCC) to enable partial nephrectomy (PN). J Clin Oncol, 2014, 32, 5s
(dopl.; abstrakt 4522).
Kolorektální karcinom: strategie pro včasnou diagnostiku
doc. MUDr. Bohumil Seifert, Ph.D. Ústav všeobecného lékařství 1. lékařské fakulty UK v Praze
1 Vybrané internetové odkazy: www.svod.cz, www.kolorektum.cz.
2 Věstník Ministerstva zdravotnictví ČR, ročník 2009, částka 1, vydán
v únoru 2009.
3 Segnan, N. – Patnick, J. – Von Karsa, L.: European guidelines for quality assurance in colorectal cancer screening and diagnosis – First edition. European Commission, Luxembourg, Publications Office of the
European Union, 2010, doi:10.2772/15379 (elektronická verze).
4 Jellema, P., et al.: Value of symptoms and additional diagnostic tests
for colorectal cancer in primary care: systematic review and meta-analysis. BMJ, 2010, 340, c1269.
5 Parente, F., et al.: A combination of faecal tests for the detection of
colon cancer: a new strategy for an appropriate selection of referral
to colonoscopy? A prospective multicenter italian study. European
Journal of Gastroenterology & Hepatology, 2012, 24, 10, s. 1145–1152,
doi: 10.1097/MEG.0b013e328355cc79.
6 Seifert, B.: Screening kolorektálního karcinomu. Příručka pro všeobecné
praktické lékaře. Maxdorf, 2012.
ACTA MEDICINAE 11/2014 FARMAKOLOGICKÁ LEČBA Kompletní literatura
Individualizace adjuvantní/neoadjuvantní terapie nádorů prsu
MUDr. Adam Paulík | prof. MUDr. Stanislav Filip, Ph.D., DrSc.
Klinika onkologie a radioterapie FN Hradec Králové
1 Modrá kniha české onkologické společnosti, 19. aktualizace, s. 263–264.
2 Eiermann, W. – Paepke, S – Appfelstaedt, J., et al.: Preoperative
treat­ment of postmenopausal breast cancer patients with letrozole:
a randomized double-blind multicenter study. Ann Oncol, 2001, 12,
s. 1527–1532.
3 Semiglazov, V. – Kletsel, A. – Semiglazov, V., et al.: Exemestane (E) vs
tamoxifen (T) as neoadjuvant endocrine therapy for postmenopauzal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). J Clin
Oncol, 2005, 23, 16S, abstrakt 530.
4 Ellis, M. E. – Suman, V. J. – Hoog, J., et al.: Randomized phase II neo­
adjuvant comparison between letrozole, anastrozole, and exemes­
tane for postmenopausal women with estrogen receptor-rich stage
2 to 3 breast cancer: clinical and biomarker outcomes and predictive
value of the baseline PAM50-based intrinsic subtype—ACOSOG
Z1031. J Clin Oncol, 2011, 29, s. 2342–2349.
5 Nielsen, T. O. – Paker, J. S. – Leung, S., et al.: A comparison of PAM50
intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Cancer Res, 2010, 16, s. 5222–5232.
6 Sgroi, D. C. – Carney, E. – Zarrella, E., et al.: Prediction of late disease
recurrence and extended adjuvant letrozole benefit by the HOXB13/
IL17BR biomarker. J Natl Cancer Inst, 2013, 105, s. 1036–1042.
7 Martin, M. – Brase, J. C. – Calvo, L., et al.: Clinical validation of the
EndoPredict test in node-positive, chemotherapy-treated ER+/HER2−
breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res, 2014, 16 (2), R38, doi: 10.1186/bcr3642.
8 Gianni, L. – Eiermann, W. – Semiglazov, V. S., et al.: Follow-up results
of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT
alone, in patients with HER2 positive locally advanced breast cancer.
Prezentováno na: 2013 ASCO Annual Meeting. Oral abstract session.
J Clin Oncol, 2013, dopl., abstrakt 503.
9 Goldhirsch, A. – Gelber, R. D. – Piccart-Gebhart, M. J., et al.: 2 years
versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 2013,
382 (9897), s. 1021–1028.
10 Gianni, L. – Pienkowski, T. – Im, Y. H., et al.: Efficacy and safety of
neoadjuvant pertuzumab and trastuzumab in women with locally
advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet
Oncol, 2012, 13, s. 25–32.
11 De Azambuja, E. – Holmes, A. P. – Piccart-Gebhart, M., et al.: Lapatinib with trastuzumab for HER2-positive early breast cancer (Neo­
ALTTO): survival outcomes of a randomised, open-label, multicentre,
phase 3 trial and their association with pathological complete res­
ponse. Lancet Oncol, 2014, 15, s. 1137–1146.
12 Piccart-Gebhart, M. – Holme, A. P. – Baselga, J., et al.: First results
from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D)
comparing one year of anti-HER2 therapy with lapatinib alone (L),
trastuzumab alone (T), their sequence (TL), or their combination
(T+L) in the adjuvant treatment of HER2-positive early breast cancer
(EBC). J Clin Oncol, 2014, 32, 5, dopl., abstrakt LBA4.
13 Sikov, W. M. – Berry, D. A. – Perou, C. M., et al.: Impact of the addition
of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly
paclitaxel (P) followed by dose-dense AC on pathologic complete
response (pCR) rates in triple-negative breast cancer (TNBC): CALGB40603(Alliance). Prezentováno na: San Antonio Breast Cancer Symposium San Antonio, TX, 2013, abstrakt S5-01.
14 Cameron, D. – Brown, J. – Dent R., et al.: Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol, 2013, 14,
s. 933–942.
15 Von Minckwitz, G. – Schneeweiss, A. – Salat, C., et al.: A randomized
phase II trial investigating the addition of carboplatin to neoadjuvant
therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). J Clin Oncol, 2013, 31, 15, dopl., abstrakt 1004.
16 Untch, M. – Rezai, M. – Loibl, S., et al.: Neoadjuvant treatment with
trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol, 2010, 28 (12), s. 2024–2031.
Nintedanib, trojitý inhibitor angiokináz
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol
1 Reck, M. – Kaiser, R. – Mellemgaard, A. – Douillard, J. Y., et al.: Docetaxel plus nintedanib versus docetaxel plus placebo in patients
with previously treated non-small-cell lung cancer (LUME-Lung 1):
a phase 3, double-blind, randomised controlled trial. Lancet Oncol,
2014, 15, s. 143–155, doi: 10.1016/S1470-2045(13)70586-2, Epub
9. 1. 2014.
2 Hanna, N. H.: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed
in patients with advanced nonsquamous non-small cell lung cancer
(Lume-lung 2) after failure of first-line chemotherapy. 2013 ASCO Annual Meeting, abstrakt 8034.
Pleurální výpotek u pacientů s chronickou myeloidní leukemií
léčených dasatinibem
MUDr. Hana Klamová, CSc. Ústav hematologie a krevní transfuze Praha
1 O‘Hare, T. – Waltrs, D. K. – Stoftregen, E. P., et al.: In vitro activity
of Bcr-Abl inhibitors BMS-354825 and AMN107 against clinicaly relevant imatinib-resistant Abl kinase domain mutants. Cancer Res
2005;65:4500–4506.
2 Hochhaus, A. – Baccarani, M. – Deininger, M., et al.: Dasatinib induces
durable cytogenetic response in patients with chronic myelogenous
leukemia in chronic phase with resistance or intolerance to imatinib.
Leukemia 2008;22:1200–1206.
3 Mauro, M. J. – Deininger, M. V.: Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22:409–429.
4 Jabbour, E. – Deininger, M. – Hochhaus, A.: Management of adverse
events associataed with tyrosine kinase inhibitors in the treatment
of chronic myeloid leukemia. Leukemia 2011;25(2):201–210.
5 de Lavallage, H. – Punnialingam, S. – Milojkovic, D.: Pleural effu­sion
in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol
2008;141:745–471.
6 Kim, D. H. – Kamel-Reid, S. – Chány, H., et al.: Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with
dasatinib therapy for Philadelphia chromosome positive leukemia.
Hae­matologica 2009;94:134–139.
7 Mustjoki, S. – Ekblom, M. – Arstila, T. P., et al.: Clonal expansion of T/
NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia
2009;23:1398–1405.
8 Apperley, J. – Cortes, J.E. – Kim, D. W., et al.: Dasatinib in the treatment
of chronic myeloid leukemia in accelerated phase after imatinib failure: the START-A trial. J Clin Oncol 2009; 27:3472–279.
9 Shah, N. P. – Kim, D. W. – Kantarjian, H. M., et al.: Dasatinib dose-optimization in chronic phase myeloid leukemia: two-year data CA180034 show equivalent long term efficacy and improved safety with
100 mg once daily dose. Blood 2008;112:3225.
10 Zackova, D. – Klamova, H. – Muzik, J., et al.: Efficacy and tolerance
of dasatinib after imatinib failure or intolerance for chronic mye­
loid leukemia patients treated in three different hospitals compare
well with results achievable in formal clinical trials. Leuk Lymphoma
2013;54(10):2310–2313.
11 Klamova, H. – Faber, E. – Zackova, D., et al.: Dasatinib in imatinib–
–resistant or intolerant CML patients: data form the clinical practice of 6 hematological centers in the Czech Republic. Neoplasma
2010;57:355–359.
12Latagliata, R. – Breccia, M. – Carmen, F., et al.: Incidence, risk factors
and management of pleural effusions during dasastinib treatment
in unselected elderly patients with chronic myelogenous leukemia.
Hematol Oncol 2013;31:103–109.
13 Quantas-Cardama, A. – Kantarjian, H. – O´Brien, S., et al.: Pleural effu­
sion in patients with chronic mylogenous leukemia treated with dasastimib after imatinib failure. J Clin Oncol 2007;25:3908–3914.
14 La Rosee, P. – Martiat, P. – Klag, T., et al.: Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with
chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol 2013;92:1345–1350.
ACTA MEDICINAE 11/2014 FARMAKOLOGICKÁ LEČBA Kompletní literatura
Troponiny jako bioindikátory určitých typů kardiotoxicity léčiv
doc. MUDr. Michaela Adamcová, Ph.D.
Ústav fyziologie, LF v Hradci Králové, Univerzita Karlova v Praze
1 Adamcová, M. – Geršl, V. – Hrdina, R. – Mělka, M. – Mazurová, Y. –
Vávrová, J. – Palička, V. – Kokštein, Z.: Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits.
J Cancer Res Clin Oncol, 1999, 125 (5), s. 268–274.
2 Adamcova, M. – Sterba, M. – Simunek, T. – Potacova, A. – Popelova, O. – Mazurova, Y. – Gersl, V.: Troponin as a marker of myocardial
damage in drug-induced cardiotoxicity. Expert Opin Drug Saf, 2005,
4, s. 457–472.
3 Adamcová, M. – Šimůnek, T. – Kaiserová, H. – Popelová, O. – Štěrba,
M. – Potáčová, A. – Vávrová, J. – Maláková, J. – Geršl, V.: In vitro and
in vivo examination of cardiac troponins as biochemical markers of
drug-induced cardiotoxicity. Toxicology, 2007, 237 (1–3), s. 218–228.
4 Adamcová, M. – Popelová-Lenčová, O. – Jirkovský, E. – Mazurová,
Y. – Geršl, V. – Štěrba, M.: Regulatory proteins of myocardium for
evaluatiton of cardiotoxicity. Acta Physiologica, 2014, 211, s. 72.
5 Berridge, B. R. – Pettit, S. – Walker, D. B. – Jaffe, A. S. – Schultze, A.
E. – Herman, E. – Reagan, W. J. – Lipshultz, S. E. – Apple, F. S. – York,
M. J.: A translational approach to detecting drug-induced cardiac injury with cardiac troponins: consensus and recommendations from
the Cardiac Troponins Biomarker Working Group of the Health and
Environmental Sciences Institute. Am Heart J, 2009, 158 (1), s. 21–29.
6 Bertinchant, J. P. – Robert, E. – Polge, A. – Marty-Double, C. – Fab­
bro-Peray, P. – Poirey, S. – Aya, G. – Juan, J. M. – Ledermann, B. – de
la Coussaye, J. E. – Dauzat, M.: Comparison of the diagnostic value
of cardiac troponin I and T determinations for detecting early myocardial damage and the relationship with histological findings after
isoprenaline-induced cardiac injury in rats. Clin Chim Acta, 2000, 298
(1–2), s. 13–28.
7 Bleuel, H. – Deschl, U. – Bertsch, T. – Bölz, G. – Rebel, W.: Diagnostic efficiency of troponin T measurements in rats with experimental
myocardial cell damage. Exp Toxicol Pathol, 1995, 47 (2–3), s. 121–127.
8 Brady, S. – York, M. – Scudamore, C. – Williams, T. – Griffiths, W. –
Turton, J.: Cardiac troponin I in isoproterenol-induced cardiac injury
in the Hanover Wistar rat: studies on low dose levels and routes of
administration. Toxicol Pathol, 2010, 38, s. 287–291.
9 Cardinale, D. – Colombo, A. – Torrisi, R., et al.: Trastuzumab-induced
cardiotoxicity: clinical and prognostic implications of troponin evaluation. J Clin Oncol, 2010, 28 (25), s. 3910–3916.
10 Cardinale, D. – Salvatici, M. – Sandri, M. T.: Role of biomarkers in cardiooncology. Clin Chem Lab Med, 2011, 49 (12), s. 1937–1948.
11 Clements, P. – Brady, S. – York, M. – Berridge, B. – Mikaelian, I. –
Nick­laus, R. – Gandhi, M. – Roman, I. – Stamp, C. – Davies, D. –
McGill, P. – Williams, T. – Pettit, S. – Walker, D.: ILSI HESI Cardiac
Troponins Working Group, Turton J. Time course characterization of
serum cardiac troponins, heart fatty acid-binding protein, and morphologic findings with isoproterenol-induced myocardial injury in
the rat. Toxicol Pathol, 2010, 38 (5), s. 703–714.
12 Cove-Smith, L. – Woodhouse, N. – Hargreaves, A. – Kirk, J. – Smith,
S. – Price, S. A. – Galvin, M., et al.: An integrated characterization of
serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. Toxicol Sci, 2014, 140 (1), s. 3–15.
13 Engle, S. K. – Jordan, W. H. – Pritt, M. L. – Chiang, A. Y., et al.: Qualification of cardiac troponin I concentration in mouse serum using
isoproterenol and implementation in pharmacology studies to accelerate drug development. Toxicol Pathol, 2009, 37, s. 617–628.
14 Hamm, C. W. – Ravkilde, J. – Gerhardt, W. L.: The prognostic value
of serum troponin T in unstable angina. N Engl J Med, 1992, 327,
s. 146–150.
15 Hausner, E. A. – Hicks, K. A. – Leighton, J. K. – Szarfman, A. –
Thompson, A. M. – Harlow, P.: Qualification of cardiac troponins for
nonclinical use: A regulatory Perspective. Regulatory Toxicology and
Pharmacology, 2013, 67, s. 108–114.
16 Herman, E. H. – Lipshultz, S. E. – Rifai, N. – Zhang, J. – Papoian, T. –
Yu, Z. X. – Takeda, K. – Ferrans, V. J.: Use of cardiac troponin T levels as
an indicator of doxorubicin-induced cardiotoxicity. Cancer Research,
1998, 58, s.195–197.
17 Herman, E. H. – Zhang, J. – Lipshultz, S. E., et al.: Correlation between serum levels of cardiac troponin T and severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol, 1999, 17,
s. 2237–2243.
18 Herman, E. H. – Ferrans, V. J.: The use of cardiac biomarkers for the
detection of drug-induced myocardial damage. In: Adams. J. E. III –
Apple, F. S. – Jaffe, A. S. – Wu, A. H. B. (eds.) – Armonk, N. Y.: Markers in
Cardiology: Current and future clinical applications. Futura Publishing
Company, Inc., 2001, s. 211–234.
19 Herman, E. H. – Lipshultz, S. E. – Ferrans, V. J.: The use of cardiac
markers to detect myocardial damage induced by chemotherapeutic agents. In: Wu, A. H. B. (ed.): Cardiac Markers. Humana Press Inc.,
Totowa, NJ, 2003, s. 87–109.
20www.ifcc.org/media/102202/IFCC_Troponin_Table_vDec_2010_FINAL_ug_L_28Jan11.pdf 21, http://www.uniprot.org.
21 Jabor, A.: Natriuretické peptidy. Roche, Praha, 2010.
22 Jirkovský, E. – Lenčová-Popelová, O. – Hroch, M. – Adamcová, M., et
al.: Early and delayed cardioprotective intervention with dexrazoxane
each show different potential for prevention of chronic anthracycline
cardiotoxicity in rabbits. Toxicology, 2013, 311, s. 191–204.
23 Katus, H. A. – Remppis, A. – Looser, S. – Hallermeier, K. – Scheffold,
T. – Kübler, W.: Enzyme-linked immunoassay of cardiac troponin T for
detection of acute myocardial infarction in patients. J Mol Cell Cardiol,
1989, 21, s. 1349–1353.
24 Katus, H. A. – Remppis, A. – Scheffold, T. – Diederich, K. W. – Kuebler, W.: Intracellular compartmentation of cardiac troponin T and its
release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol, 1991, 67, s. 1360–1367.
25 Koh, E. – Nakamura, T. – Takahashi, H.: Troponin T and brain natri­
uretic peptide as predictors for adriamycin-induced cardiomyopathy
in rats. Circ J, 2004, 68 (2), s. 163–167.
26 Kurata, M. – Iidaka, T. – Sasayama, Y. – Fukushima, T. – Sakimura,
M. – Shirai, N.: Correlation among clinicopathological parameters of
myocardial damage in rats treated with isoproterenol. Exp Anim, 2007,
56 (1), s. 57–62.
27 Lang, K. – Sigusch, H. H. – Börner, A. – Hoffmann, M., et al.: Minimal
myocardial lesions caused by endomyocardial biopsy can be detected by a commercially available cardiac troponin T enzyme-linked
immunosorbent assay. Eur J Clin Inv, 1996, 26, s. 451–453.
28 Mair, J. – Artner-Dworzak, E. – Leichtner, P., et al.: Cardiac troponin T diagnosis of acute myocardial infarction. Clin Chem, 1991, 37,
s. 845–852.
29 Mladenka, P. – Hrdina, R. – Bobrovová, Z. – Semecky, V. – Vávrová,
J. – Holecková, M. – Palicka, V. – Mazurová, Y. – Nachtigal, P.: Cardiac
biomarkers in a model of acute catecholamine cardiotoxicity. Hum
Exp Toxicol, 2009, 28 (10), s. 631–640.
30 Newby, L. K. – Rodriguez, I. – Finkle, J. – Becker, R. C. – Hicks, K. A.,
et al.: Troponin measurements during drug development-considerations for monitoring and management of potential cardiotoxicity: an
educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and
Drug Administration. Am Heart J, 2011, 162 (1), s. 64–73.
31 O’Brien, P. J. – Dameron, G. W. – Beck, M. L., et al.: Cardiac troponin
T is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab Anim Sci, 1997, 47 (5), s. 486–495.
32 O’Brien, P. J.: Blood cardiac troponin in toxic myocardial injury: archetype of a translational safety biomarker. Expert Rev Mol Diagn, 2006,
6 (5), s. 685–702.
33 O’Brien, P. J.: Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology, 2008,
245 (3), s. 206–218.
34 Popelová, O. – Štěrba, M. – Šimůnek, T., et al.: Deferiprone does not
protect against chronic anthracycline cardiotoxicity in vivo. J Pharmacol Exp Ther, 2008, 326 (1), s. 259–269.
35 Popelová, O. – Štěrba, M. – Hašková, P. – Šimůnek, T. – Hroch, M. –
Gunčova, I., et al.: Dexrazoxane-afforded protection against chronic
anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. Br J Cancer, 2009, 101, s. 792–802.
36 Reagan, W. J.: Troponin as a biomarker of cardiac toxicity: past, present, and future. Toxicol Pathol, 2010, 38 (7), s. 1134–1137.
37 Simunek, T. – Klimtova, I. – Kaplanova, J., et al.: Rabbit model for in
vivo study of anthracycline induced heart failure and for the evaluation of protective agents. Eur J Heart Fail, 2004, 6, s. 377–387.
38 Stevens, J. L. – Baker, T. K.: The future of drug safety testing: expaning the view and narrowing the focus. Drug Discovery Today, 2009,
14 (3–4), s. 162–167.
39 Štěrba, M. – Šimůnek, T. – Popelová, O., et al.: Early detection of
anthracycline cardiotoxicity in a rabbit model: left ventricle filling
pattern versus troponin T determination. Physiol Res, 2007, 56 (5),
s. 535–545.
40 Štěrba, M. – Popelova, O. – Lenco, J. – Fucikova, A., et al.: Proteomic
insights into chronic anthracycline cardiotoxicity. J Mol Cell Cardiol,
2011, 50, s. 849–862.
41 Tonomura, Y. – Mori, Y. – Torii, M. – Uehara, T.: Evaluation of the usefulness of biomarkers for cardiac and skeletal myotoxicity in rats. Toxicology, 2009, 266, s. 48–54.
42 Wallace, K. B. – Hausner, E. – Herman, E.: Serum troponins as biomarkers of drug-induced cardiotoxicity. Toxicol Pathol, 2004, 32, s. 106–121.
43 White, H. D.: Pathobiology of troponin elevations: do elevations occur
with myocardial ischemia as well as necrosis? J Am Coll Cardiol, 2011,
57, s. 2406–2408.
44 Wilkinson, J. M. – Grand, R. J. A.: Comparison of amino acid sequence of troponin I from different striated muscles. Nature, 1978, 271,
s. 31–35.
45 York, M. – Scudamore, C. – Brady, S., et al.: Characterization of troponin responses in isoproterenol-induced cardiac injury in the Hanover
Wistar rat. Toxicol Pathol, 2007, 35, s. 606–617.
46 Zhang, J. – Knapton, A. – Lipshultz, S. E. – Weaver, J. L. – Herman, E.
H.: Isoproterenol-induced cardiotoxicity in Sprague-Dawley rats: cor­
relation of reversible and irreversible myocardial injury with release
of cardiac troponin T and roles of iNOS in myocardial injury. Toxicol
Pathol, 2008, 36, s. 277–278.
Glukokortikoidy šetřící léčba u systémového lupus
erythematodes – zaměřeno na belimumab
MUDr. Hana Ciferská, Ph.D. Revmatologický ústav a Revmatologická klinika 1. LF UK a VFN, Praha
MUDr. Jan Vachek Klinika nefrologie VFN a 1. LF UK, Praha
1 Domic, R. T. – Ramsey-Goldman, R. – Manzi, S.: Epidemiology and
classification of systemic lupus erythematosus. In: Hochberg, M. C. –
Silman, A. J. – Smolen, J. S. – Weinblatt, M. E. – Weisman, M. H., editors.: Rheumatology. 4. vydání, Philadelphia (PA), Mosby-Elsevier, 2008,
s. 1211–1216.
2 Hochberg, M. C., et al.: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1997, 40, s. 1725.
3 Hochberg, M. C. – Silman, A. J. – Smolen, J. S. – Weinblatt, M. E. – Weisman, M. H., editors.: Epidemiology and classification of systemic lupus
erythematosus. In: Rheumatology. 4. vydání, Philadelphia (PA), Mosby-Elsevier, 2008, s. 1211–1216.
4 Boneparth, A. – Davidson, A.: B-cell activating factor targeted therapy and lupus. Arthritis Res Ther. 2012,14, dopl. 4, S2.
5 Stohl, W.: BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists. Curr Dir
Autoimmun, 2005, 8, s. 289–304.
6 Treml, J. F. – Hao, Y. – Stadanlick, J. E., et al.: The BLyS family: toward
a molecular understanding of B cell homeostasis. Cell Biochem Biophys, 2009, 53, s. 1–16.
7 Furie, R. – Petri, M. – Zamani, O. – Cervera, R., et al.: BLISS-76 Study
Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator,
in patients with systemic lupus erythematosus. Arthritis Rheum, 2011,
ACTA MEDICINAE 11/2014 FARMAKOLOGICKÁ LEČBA Kompletní literatura
63, s. 3918–3930.
8 van Vollenhoven, R. F. – Mosca, M. – Bertsias, G., et al.: Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis, 2014, 73, s. 958–967.
9 Horák, P. – Tezová, D. – Závada, Z., et al.: Doporučení ČRS pro léčbu
nemocných se SLE. Čes Revmatol, 2013, 21, 3, s. 110–122.
10 Gladman, D. D. – Urowitz, M. D. – Rahman, P. – Ibañez, D. – Tam, L.
S.: Acctual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol, 2003, 30, s. 1955–1959.
11 Hamer, M. – Hernán, M. A. – Zhang, Y. – Cotter, D. – Petri, M.: Prednisone, lupus activity, and permanent organ damage. J Rheumatol,
2009, 36, s. 560–564.
12 Lu, N. Z. – Cidlowski, J. A.: The origin and functions of multiple human glucocorticoid receptor isoforms. Ann N Y Acad Sci, 2004, 1024,
s. 102–123.
13 Stahn, C. – Buttgereit, F.: Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol, 2008, 4, s. 525–533.
14 Rhen, T. – Cidlowski, J. A.: Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med, 2005, 353,
s. 1711–1723.
15 Gatto, M. – Kiss, E. – Naparstek, Y. – Doria, A.: In-/off-label use of biologic therapy in systemic lupus erythematosus. BMC Med, 2014, 17,
12, s. 30.
16 Stohl, W.: Future prospects in biologic therapy for systemic lupus
erythematosus. Nat Rev Rheumatol, 2013, 9, s. 705–720.
17 Mosca, M. – Tani, C. – Aringer, M. – Bombardieri, S., et al.: European
League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in
observational studies. Ann Rheum Dis, 2010, 69, s. 1269–1274.
18 Baker, K. P. – Edwards, B. M. – Main, S. H., et al.: Generation and
characterization of LymphoStat-B, a human monoclonal antibody
that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum, 2003, 48, s. 3253–3265.
19 Human Genome Science BENLYSTA (belimumab), dostupné z:
www.hgsi.com/belimumab.html, vyhledáno 3. 12. 2014.
20 van Vollenhoven, R. F. – Gallacher, A. – Navarra, S., et al.: Belimumab, a BLyS-Specific Inhibitor, Reduced Corticosteroid Use in Patients
with Active SLE: Results from the Phase 3 BLISS-52 and -76 Studies
(abstrakt). Arthritis Rheum, 2010, 62, dopl. 10, s. 451.
21 Petri, M. – Levy, R. A. – Merill, J. T., et al.: Belimumab, a BLyS-specific
inhibitor, reduced disease activity, flares, and prednisone use in pa­
tients with seropositive SLE: combined efficacy results from the phase
3 BLISS-52 and -76 studies. Arthritis Rheum, 2010, 62, dopl. 10, s. 190.
22 Cervera, R. – Furie, R. – Levy, R., et al.: Relationship of belimumab
treat­ment response with corticoid use and severe flares in patients
with SLE: BLISS-52 and BLISS-76. Ann Rheum Dis, 2011, 70, dopl. 3,
s. 321.
23 Navarra, S. V. – Guzmán, R. M. – Gallacher, A. E., et al.: BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active
systemic lupus erythematosus: a randomised, placebo-controlled,
phase 3 trial. Lancet, 2011, 26, 377, s. 721–731.
24 Furie, R. – Petri, M. – Zamani, O. – Cervera, R., et al.: BLISS-76 Study
Group: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator,
in patients with systemic lupus erythematosus. Arthritis Rheum, 2011,
63, s. 3918–3930.
25 Navarra, S. – Ilianova, E. – Bae, S. C., et al.: Belimumab, a BLyS-specific
inhibitor, reduced disease activity, flares, and steroid use in pa­tients
with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Ann Rheum Dis, 2010, 69, dopl. 3, s. 556.
26 Collins, C. E. – Oglesby, M. – McGuire, A., et al.: 12-Month Outcomes
Associated With Belimumab In Patients With Systemic Lupus Erythematosus In Clinical Practice Settings: The Observe Study (OP0048).
Ann Rheum Dis, 2014, 73, dopl. 2.
27 Ginzler, E. M. – Wallace, D. J. – Merrillo, J. T., et al.: LBSL02/99 Study Group: Disease control and safety of belimumab plus standard
therapy over 7 years in patients with systemic lupus erythematosus.
J Rheumatol, 2014, 41, s. 300–309.
Mirabegron: nové možnosti terapie hyperaktivního
močového měchýře
MUDr. Roman Staněk Urologické oddělení Slezské nemocnice Opava
1 Sein, A. J.: Pharmacologic options for the overactive bladder. Urology
Review, 1998, 51(2A dopl.), s. 43–47.
2 Abrams, P. – Freeman, R. – Anderström, C. – Mattiasson, A.: Tolterodine, a new antimuscarinic agent: as effective but better tolerated
than oxybutynin in patients with an overactive bladder. Br J Urol, 1998,
81, s. 801–810.
3 Abrams, P. – Cardozo, L. – Fall, M. – Griffiths, D. – Rosier, P. – Ulmsten,
U. – van Kerrebroeck, P. – Victor, A. – Wein, A.: The standardisation
of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.
Neurourol Urodyn, 2002, 21, s. 167–178.
4 Irwin, D. E. – Milsom, I. – Hunskaar, S. – Reilly, K. – Kopp, Z. –
Herschorn, S. – Coyne, K. – Kelleher, C. – Hampel, C. – Artibani,
W. – Abrams, P.: Population-based survey of urinary incontinence,
overactive bladder, and other lower urinary tract symptoms in five
countries: results of the EPIC study. Eur Urol, 2006, 50, s. 1306–1314.
5 Milsom, I. – Abrams, P. – Cardozo, L. – Roberts, R. G. – Thüroff, J. –
Wein, A. J.: How widespread are the symptoms of an overactive
bladder and how are they managed? A population-based prevalence study. BJU Int, 2001, 87, s. 760–766.
6 Stewart, W. F. – Van Rooyen, J. B. – Cundiff, G. W. – Abrams, P. – Herzog, A. R. – Corey, R. – Hunt, T. L. – Wein, A. J.: Prevalence and burden of overactive bladder in the United States. World J Urol, 2003, 20,
s. 327–336, Epub 15. 11. 2002.
7 Krhut, J. – Zachoval, R. – Martan, A. – Němec, D. – Havránek, O. –
Sýkora, R. – Švábím, K. – Hanuš, T.: Prevalence symptomů hyperaktivního měchýře u pacientů urologických ambulancí. Ces Urol, 2011,
15, s. 181–188.
8 Reproductive and Urologic Drug Advisory Committee, 5. 4. 2012.
9 Dale, P. R. – Cernecka, H. – Schmidt, M. – Bowling, M. R. – Charlton,
S. J. – Pieper, M. P. – Michel, M. C.: The pharmacological rationale for
combining muscarinic receptor antagonist and β adrenoreceptor
agonist in the treatment of airway and bladder disease. Current Opinion in Pharmacology, 2014, 16, s. 31–42.
10 Takeda, M. – Obara, K. – Mizusawa, T. – Tomita, Y. – Arai, K. – Tsutsui, T., et al.: Evidence for β3-adrenoceptor subtypes in relaxation of
the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther, 288, 1999,
s. 1367–1373.
11 Takeda, H. – Yamazaki, Y. – Akahane, M. – Igawa, Y. – Ajisawa, Y. –
Nishizawa, O.: Role of the β(3)-adrenoceptor in urine storage in the
rat: comparison between the selective β(3)-adrenoceptor agonist,
CL316, 243, and various smooth muscle relaxants. J Pharmacol Exp
Ther, 2000, 293, s. 939–945.
12 Nomiya, M. – Yamaguchi, O.: A quantitative analysis of mRNA expres­
sion of a1 and b-adrenoceptor subtypes and their functional roles in
human normal and obstructed bladders. J Urol, 2003, 170, s. 649–653.
13 Andersson, K. – Chapple, C. – Cardozo, L. – Cruz, F. – Hashim,
H. – Michel, M. C., et al.: Pharmacological treatment of urinary incontinence. In: Abrams, P. – Cardozo, L. – Khoury, S. – Wein, A. (eds): Incontinence, 4th International Consultation on Incontinence. Plymouth,
2009. UK, Plymbridge Distributors, s. 631–699.
14 Attachment 1: Product information for AusPAR Betmiga mirabegron
Astellas Pharma Australia Pty Ltd PM-2012-01928-3-3 Date of Finalisation 9. 1. 2014. This Product Information was approved at the time
this AusPAR was published.
15 Krauwinkel, W. – van Gelderen, E. – Groen, M. – Schaddelee, M. –
de Koning, P.: An openlabel crossover study to evaluate the effect
of multiple doses of mirabegron on the pharmacokinetics of the CYP2D6 substrate desipramine in healthy subjects. Clin Pharmacol Ther,
2010, 87(dopl. 1), abstrakt PI-43.
16 MYRBETRIO™ (mirabegron) extended-release tablets Prescribing Information, Astellas Pharmaceuticals, 2012.
17 Yamaguchi, O.: Β-3-adrenoreceptors in human detrusor muscle. Urology, 2002, 59 (dopl. 5A), s. 25–29.
18 Mirabegron (Myrbetriq) National Drug Monograph 21. Květen 2013,
VA Phramacy Benefits Management Services, Medical Advisory Panel
and VISN Pharmacist Ececutives.
19 Takusagawa, S. – van Lier, J. – Suzuki, K. – Nagata, M. – Meijer, J. –
Krauwinkel, W., et al.: Absorption, metabolism and excretion of [14C]
mirabegron (YM178), a potent and selective β3-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab
Dispos, 2012, 40, s. 815–824.
20 Chapple, Ch. R. – Dvorak, V. – Radziszewski, P. – van Kerrebroeck,
P. – Wyndaele, J. J., et al., on behalf of the Dragon Investigator Group:
A phase II dose-ranging study of mirabegron in patiens with over­
active bladder. Int Urogynecol J, 2013, 24, s. 1447–1458.
21 Chapple, C. R. – Wyndaele, J. J. – van Kerrebroeck, P., et al.:
Dose-ranging study of once-daily Mirabegron (YM178), a novel selective 3-adrenoceptor agonist, in patients with overactive bladder
(OAB). Poster prezentován na 25th Annual European Association of
Urology Meeting, 16.–20. dubna 2010, Barcelona, Španělsko. Poster
774.
22 Khullar, V. – Cambronero, J. – Angulo, J., et al.: Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for
overactive bladder (OAB): post hoc analysis of a prospective, randomised, active- and placebo-controlled European–Australian Phase
III trial. Poster prezentován na 28th Annual European Association of
Urology Meeting, 24.–28. února 2012, Paříž, Francie. Poster 684.
23 Khullar, V. – Amarenco, G. – Angulo, J. C., et al.: Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with
overactive bladder: results from a randomized European–Austra­
lian Phase 3 Trial. Eur Urol, 2013, 63, s. 283–295, doi: 10.1016/j.eururo.2012.10.016, Epub 6. 11. 2012.
24 Chapple, C. R. – Kaplan, S. – Mitcheson, H. D., et al.: Randomized,
double-blind, active-controlled phase III study to assess 12-month safety and efficacy of mirabegron, a β3-adrenoceptor agonist, in over­
active bladder (OAB). Eur Urol, 2013, 63, s. 296–305, doi: 10.1016/j.
eururo.2012.10.048, Epub 6. 11. 2012.
25 Kato, K. – Furuhashi, K. – Suzuki, K. – Murase, T. – Sato, E. – Gotoh,
M.: Overactive bladder and glaucoma: a survey at outpatient clinics
in Japan. Int J Urol, 2007, 14, s. 595–597.
26 Martin, N. E. – Lewis, R. A. – Vogel, R., et al.: Randomised, double-blind, placebo-controlled study to assess the ocular safety of mirabegron in normotensive IOP research subjects. Poster prezentován na
28th Annual European Association of Urology Meeting, 24.–28. února
2012, Paříž, Francie. Poster 686.
27 Yeaw, J., et al.: J Manag Care Pharm. 2009, 15, s. 728–740.
28 Ogihara, K. – Kaguyama, H. – Sakamoto, H. – Aonuma, K. –
Matsuda, K. – Nakahira, Y. – Yanaihara, H. – Asakura, H.: Persistence
with mirabegron in patiens with overactive bladder: a comparative
study of mirabegron and antimuskarinic: poster 576, 2014.
29 Maman, K. – Aballea, S. – Nazir J. – Desroziers K. – Neine, M. E. – Sid­
diqui, E, – Odeyemi I. – Hakimi, Z.: Comparative efficacy and safety of
medical treatments for the management of overactive bladder: A systematic literature review and mixed treatment comparison. Euro­pean
Urology, 2014, 65, s. 755–765.
Metoprolol
prof. MUDr. Jan Bultas, CSc. Farmakologický ústav 3. LF UK Praha
1 Abrahamsson, T. – Ek, B. – Nerme, V.: The β1- and β2-adrenoceptor
affinity of atenolol and metoprolol. A receptor-binding study performed with different radioligands in tissues from the rat, the guinea
pig and man. Biochem Pharmacol, 1988, 37, s. 203–208.
2 Self, T. H. – Wallace, J. L. – Soberman, J. E.: Cardioselective β-blocker
treatment of hypertension in patients with asthma: when do benefits outweigh risks? J Asthma, 2012, 49, s. 947–951.
3 Batty, J. A. – Hall, A. S. – White, H. L. – Wikstrand, J., et al.: An
investigation of CYP2D6 genotype and response to metoprolol CR/
XL during dose titration in patients with heart failure: a MERIT-HF
substudy.Clin Pharmacol Ther, 2014, 95, s. 321–330.
4 Law, M. R. – Morfia, J. K. – Wald, N. J.: Use of blood pressure lowering
ACTA MEDICINAE 11/2014 FARMAKOLOGICKÁ LEČBA Kompletní literatura
drugs in the prevention of cardiovascular disease: Meta-analysis of
147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 2009, 338, s. b1665.
5 Wikstrand, – J. Arnold, I. – Tomilehto, J., et al.: Metoprolol versus
thiazide diuretics in hypertension. Morbidity results from the MAPHY
Study. Hypertension, 1991, 17, s. 579–588.
6 Heffernan, K. S. – Suryadevara R, – Patvardhan E. A., et al.: Effect
of atenolol vs metoprolol succinate on vascular function in patients
with hypertension. Clin Cardiol, 2011, 34, s. 39–44.
7 Wikstrand, J. – Arnold, I. – Olsson, G., et al.: Primary prevention
with metoprolol in patients with hypertension. JAMA, 1988, 259,
s. 1976–1982.
8 Galeeva, Z. M, – Galiavich, A. S.: Efficacy and tolerability of metoprolol retard in the treatment of patients with arterial hypertension and
ischemic heart disease combined with type 2 diabetes mellitus. Kardiologiia, 2009, 49, s. 25–27.
9 Espinola-Klein, C. – Weisser, G. – Jagodzinski, A., et al.: β-Blockers
in patients with intermittent claudication and arterial hypertension:
results from the nebivolol or metoprolol in arterial occlusive disease
trial. Hypertension, 2011, 58, s. 148–154.
10 Batisky, D. L. – Sorof, J. M. – Sugg, J., et al.: Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16
years of age: a clinical trial experience. J Pediatr, 2007, 150, s. 134–139.
11Petersen, K. M. – Jimenez-Solem, E. – Andersen, J. T., et al.: β-Blocker treatment during pregnancy and adverse pregnancy outcomes:
a nationwide population-based cohort study. BMJ, 2012, 2, s. e001185,
doi: 10.1136.
12 Tomei, G. – Mosti, G. – Veltri, M., et al.: Effect of metoprolol on the
exercise tolerance in patients with stable angina pectoris. G Ital Cardiol, 1978, 8, s. 1286–1292.
13 Uusitalo, A. – Keyriläinen, O. – Johnsson, G. A.: dose-response study
on metoprolol in angina pectoris. Ann Clin Res, 1981, 13, s. 54–57.
14 Hjemdahl, P. – Ericsson, S. V. – Held, C., et al.: Favourable long term
prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS). Heart, 2006, 92, s. 177–182.
15 Hjalmarson, A. – Elmfeldt, D. – Herlitz, J., et al.: Effect on mortality
of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet, 1981, 2, s. 823–827.
16 Salathia, K. S. – Barber, J. M. – McIlmoyle, E. L., et al.: Very early intervention with metoprolol in suspected acute myocardial infarction.
Eur Heart J, 1985, 6, s. 190–198.
17 Manger, Cats. V. – van Capelle, F. J. L. – Lie, K. I., et al.: Effect of treat­
ment with 2× 100 mg metoprolol on mortality in a single-center study with low placebo mortality rate after infarction. Circulation, 1983,
68, s. 181.
18 Olsson, G. – Rehnqvist, N. – Sjögren, A., et al.: Long-term treatment
with metoprolol after myocardial infarction: effect on 3 year mortality
and morbidity. J Am Coll Cardiol, 1985, 5, s. 1428–1437.
19 Hjalmarson, A. – Elmfeldt, D. – Herlitz. J., et al.: Effect on mortality
of metoprolol in acute myocardial infarction. A randomized double-blind trial. Munch Med Wochenschr, 1982, 124, s. 32–45.
20 MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart
failure: Metoprolol CR/XL Randomized Intervention Trial In Congestive Heart Failure (MERIT-HF). Lancet, 1999, 353, s. 2001–2007.
21 Hjalmarson, A. – Goldstein, S. – Fagerberg, B., et al.: Effects of controlled-release metoprolol on total mortality, hospitalizations, and
well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA,
2000, 283, s. 1295–1302.
22 Poole-Wilson, P. A., – Swedberg, K. – Cleland, J. G., et al.: Compari­son
of carvedilol and metoprolol on clinical outcomes in patients with
chronic heart failure in the Carvedilol Or Metoprolol European Trial
(COMET): randomised controlled trial. Lancet, 2003, 362, s. 7–13.
23 Remme, W. J. – Cleland, J. G. – Erhardt, L., et al.: Effect of carvedilol
and metoprolol on the mode of death in patients with heart failure.
Eur J Heart Fail, 2007, 9, s. 1128–1135.
24 Wikstrand, J. – Wedel, H. – Castagno, D. – McMurray, J. J.: The large-scale placebo-controlled β-blocker studies in systolic heart failure
revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Intern Med, 2014, 275,
s. 134–143.
25 Amsterdam, E. A. – Kulcyski, J. – Ridgeway, M. G., et al.: Efficacy of
cardioselective β-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias.
J Clin Pharmacol, 1991, 31, s. 714–718.
26 Kangasniemi, P. – Andersen, A. R. – Anderson, P. G., et al.: Classic
migraine: effective prophylaxis with metoprolol. Cephalalgia, 1987, 7,
s. 231–238.
27 Brixius, K. – Middeke, M. – Lichtenthal, A., et al.: Nitric oxide, erectile dysfunction and β-blocker treatment (MR NOED study): benefit of
nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol
Physiol, 2007, 34, s. 327–331.
28 Molden, E. – Spigset, O.: Interactions between metoprolol and antidepressants. Tidsskr Nor Laegeforen, 2011, 131, s. 1777–1779.
29 Fukumoto, K. – Kobayashi, T. – Tachibana, K., et al.: Effect of amio­
da­rone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. Drug Metab Pharmacokinet, 2006, 21,
s. 501–505.
30 Blake, C. M. – Kharasch, E. D. – Schwab, M. – Nagele, P. A.: Eta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin Pharmacol Ther, 2013, 94, s. 394–399.
31 Pasternak, B. – Svanström, H. – Melbye, M., et al.: Association of
treatment with carvedilol vs metoprolol succinate and mortality in
patients with heart failure. JAMA Intern Med, 31. 8. 2014, doi: 10.1001/
jamainternmed.2014.3258.
AMESOS – fixní kombinace lisinoprilu a amlodipinu
v léčbě hypertenze
MUDr. Jiří Slíva, MD., Ph.D. Ústavy farmakologie 2. a 3. LF UK Praha
1 Murdoch, D. – Heel, R. C.: Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs, 1991, 41, s. 478–505.
2 Goa, K. L. – Haria, M. – Wilde, M. I.: Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes
mellitus. Drugs, 1997, 53, s. 1081–1105.
3 Bramley, T. J. – Gerbino, P. P. – Nightengale, B. S. – Frech-Tamas,
F.: Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag
Care Pharm, 2006, 12, s. 239–245.
4 Corrao, G. – Nicotra, F. – Parodi, A., et al.: Cardiovascular protection
by initial and subsequent combination of antihypertensive drugs in
daily life practice. Hypertension, 2011, 58, s. 566–572.
5 Dickson, M. – Plauschinat, C. A.: Compliance with antihypertensive
therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs, 2008, 8, s. 45–50.
6 Randomised placebo-controlled trial of lisinopril in normotensive
patients with insulin-dependent diabetes and normoalbuminuria
or microalbuminuria. The EUCLID Study Group. Lancet, 1997, 349,
s. 1787–1792.
7 Abraham, G. – Boda, K. – Legrady, P. – Letoha, A.: The effect of Lisopress® treatment on ambulatory blood pressure and urinary microalbumin excretion in patients with hypertension and diabetes.
Hypertension and nephrology, 2003, 7, s. 13–20.
8 Pilote, L. – Abrahamowicz, M. – Eisenberg, M. – Humphries, K. –
Behlouli, H. – Tu, J. V.: Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive
heart failure. CMAJ, 2008, 178, s. 1303–1311.
9 Pall, D. – Katona, E. – Juhasz, M. – Paragh, G.: Prevention of target
organ damage with modern antihypertensive agents. Orv Hetil, 2006,
147, s. 1505–1511.
10 Farsang, C. – Abraham, G. – Kovacs, P. – Karanyi, Z. – Ofner, P.: The
effectivity and safety of Amlodipin-Lisinopril Fix-combination in patients with ESSential hypertension (ALFESS study). Hypertension and
nephrology, 2009, 13, s. 81–88.
11 Krupička, J. – Souček, M. – Widimský, J.jr. – Franc, P.: Projekt Györgyi – neintervenční sledování účinnosti a tolerance léčby hypertenze
přípravkem Amesos prostřednictvím 24hodinové kontroly krevního
tlaku. Acta medicinae: Vnitřní lékařství, 2014, 9, s. 50–55.
Farmakologická léčba obezity a diabetu
prof. MUDr. Martin Haluzík, DrSc. III. interní klinika 1. LF UK a VFN, Praha
Kompletní seznam je k dispozici u autora
1 O’Rahilly, S.: Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. BMJ, 1997, 314,
s. 955–959.
2 Reaven, G.: Metabolic syndrome: pathophysiology and implications
for management of cardiovascular disease. Circulation, 2002, 106,
s. 286–288.
3 Reaven, G. – Abbasi, F. – McLaughlin, T.: Obesity, insulin resistance,
and cardiovascular disease. Recent progress in hormone research, 2004,
59, s. 207–223.
4 Despres, J. P.: Cardiovascular disease under the influence of excess
visceral fat. Crit Pathw Cardiol, 2007, 6, s. 51–59.
5 Dolinkova, M. – Dostalova, I. – Lacinova, Z., et al.: The endocrine
profile of subcutaneous and visceral adipose tissue of obese patients.
Molecular and cellular endocrinology, 2008, 291, s. 63–70.
6 Bluher, M.: Adipose tissue dysfunction in obesity. Exp Clin Endocrinol
Diabetes, 2009, 117, s. 241–250.
7 Sjostrom, L. – Narbro, K. – Sjostrom, C. D., et al.: Effects of bariatric
surgery on mortality in Swedish obese subjects. The New England
Journal of Medicine, 2007, 357, s. 741–752.
8 Borghouts, L. B. – Keizer, H. A.: Exercise and insulin sensitivity: a review. International Journal of Sports Medicine, 2000, 21, s. 1–12.
9 Delahanty, L. M. – Halford, B. N.: The role of diet behaviors in achieving improved glycemic control in intensively treated patients in
the Diabetes Control and Complications Trial. Diabetes Care, 1993,
16, s. 1453–1458.
10 Dixon, J. B. – le Roux, C. W. – Rubino, F. – Zimmet, P.: Bariatric surgery
for type 2 diabetes. Lancet, 2012, 379, s. 2300–2311.
11Fried Mea: Bariatrická a metabolická chirurgie. Praha, Mladá fronta,
2011.
12 Maetzel, A. – Ruof, J. – Covington, M. – Wolf, A.: Economic evalua­
tion of orlistat in overweight and obese patients with type 2 diabetes
mellitus. Pharmacoeconomics, 2003, 21, s. 501–512.
13 Bray, G. A. – Ryan, D. H.: Update on obesity pharmacotherapy. Annals
of the New York Academy of Sciences, 2014, 1311, s. 1–13.
14 Svačina, Š. – Sucharda, P. – Stránská, Z. – Matoulek, M.: Perspective of
obesity pharmacotherapy. Casopis lekaru ceskych, 2014, 153, s. 127–130.
15 Cummings, D. E.: Endocrine mechanisms mediating remission of
diabetes after gastric bypass surgery. International Journal of Obesity
(2005) 2009, 33, dopl. 1, s. S33–S40.
16 Wohl, P. – Krušinová, E. – Kratochvílová, S., et al.: Inzulinová rezistence u diabetiků – metabolická inflexibilita. DMEV, 2005, 8, s. 174–178.
17 Haluzík, M., et al.: Praktická léčba diabetu. Praha, Mladá fronta, 2009.
18 Blaschke, F. – Spanheimer, R. – Khan, M. – Law, R. E.: Vascular effects
of TZDs: New implications. Vascular Pharmacology, 2006.
19 Ampudia-Blasco, F. J. – Rossetti, P. – Ascaso, J. F.: Basal plus Basal-bolus approach in type 2 diabetes. Diabetes technology & therapeutics,
2011, 13, dopl. 1, s. S75–S83.
20 Haluzík, M. – Svačina, Š.: Inkretinová léčba diabetu. Praha, Mladá Fronta, 2010.
21 Deacon, C. F. – Mannucci, E. – Ahren, B.: Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4
inhibitors as add-on therapy to metformin in subjects with type 2
diabetes-a review and meta analysis. Diabetes, Obesity & Metabolism,
2012, 14, s. 762–767.
22 Abdul-Ghani, M. A. – DeFronzo, R. A.: Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2
diabetes mellitus. Endocrine practice, 2008, 14, s. 782–790.
23 Anderson, S. L. – Marrs, J. C.: Dapagliflozin for the treatment of type
2 diabetes. The Annals of Pharmacotherapy, 2012, 46, s. 590–598.
ACTA MEDICINAE 11/2014 FARMAKOLOGICKÁ LEČBA Kompletní literatura
Praktické využití fixní kombinace perindopril/indapamid
u nemocného s metabolickým syndromem
doc. MUDr. Jitka Seidlerová, Ph.D. Lékařská fakulta v Plzni, Univerzita Karlova v Praze,
Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova v Praze, Plzeň
1 Filipovský, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi.
Vnitř Lék, 2012, 58, s. 785–801.
2 Cífková, R., et al.: Prevalence základních kardiovaskulárních rizikových
faktorů v české populaci v letech 2006–2009. Studie Czech post-MONICA. Cor et Vasa, 2011, 53, s. 220–229.
3 Alberti, K. G., et al.: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force
on Epidemiology and Prevention; National Heart, Lung, and Blood
Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the
Study of Obesity. Circulation, 2009, 120, s. 1640–1645.
4 van Vark, L. C., et al.: Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving
158,998 patients. Eur Heart J, 2012, 33, s. 2088–2097.
5 Patel, A., et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients
with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet, 2007, 370, s. 829–840.
6 Beckett, N. S., et al.: Treatment of hypertension in patients 80 years
of age or older. N Engl J Med, 2008, 358, s. 1887–1898.
7 Dahlof, B., et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required
versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering
Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet,
2005, 366, s. 895–906.
8 Zoungas, S., et al.: Follow-up of blood-pressure lowering and glucose
control in type 2 diabetes. N Engl J Med, 2014, 371, s. 1392–1406.
9 PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals
with previous stroke or transient ischaemic attack. Lancet, 2001, 358,
s. 1033–1041.
10 Dahlof, B., et al.: Perindopril/indapamide combination more effective
than enalapril in reducing blood pressure and left ventricular mass:
the PICXEL study. J Hypertens, 2005, 23, s. 2063–2070.
11 Mogensen, C. E, et al.: Effect of low-dose perindopril/indapamide on
albuminuria in diabetes: preterax in albuminuria regression: PREMIER.
Hypertension, 2003, 41, s. 1063–1071.
12 Mourad, J. J., et al.: Improvement of impaired coronary vasodilator
reserve in hypertensive patients by low-dose ACE inhibitor/diuretic
therapy: a pilot PET study. J Renin Angiotensin Aldosterone Syst, 2003,
4, s. 94–95.
13 Asmar, R. G., et al.: Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination. J Hypertens Suppl, 2001,
19, s. 15–20.
14 Bangalore, S. – Kamalakkannan, G. – Parkar, S. – Nessedli, F. H.: Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med, 2007, 120, s. 713–719.
15 Kuo, S. W., et al.: Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens, 2003, 16,
s. 623–628.
16 Ames, R. P.: A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide
and with thiazides. Am J Cardiol, 1996, 77 s. 12b–16b.
17 Mancia, G. – Parodi, A. – Merlino, L. – Corrao, G.: Heterogeneity in
antihypertensive treatment discontinuation between drugs belonging to the same class. J Hypertens, 2011, 29, s. 1012–1018.
18 Agarwal, R.: Hypertension, hypokalemia, and thiazide-induced diabetes: a 3-way connection. Hypertension, 2008, 52, s. 1012–1013.
Personalizovaná léčba deprese
prof. MUDr. Jiří Raboch, DrSc. Psychiatrická klinika 1. LF UK a VFN
1 Barber, J. P. – Muenz, L. R.: The role of avoidance and obsessiveness
in matching patiens to cognitive and interpersonal psychotherapy:
Empiricalfindings fromt the Treatment for Depression Collaborative
Research Program. J Consult Clin Psychol, 1996, 64, s. 951–958.
2 Bauer, M., et al.: World Federation of Societies of Biological Psy­chiatry
(WFSBP) Guidelines for Biological Treatment of Unipolar Depressive
Disorders, Part 1: Update 2013 on the acute and continuation treat­
ment of unipolar depressive disorders. The World J Biol Psychiatry,
2013, 14, s. 334–385.
3 DeRubeis, R. J., et al.: The Personalized Adnvantage Index: translating
research on prediction into individualized treatment recommenda­
tions. A demonstrativ. PLOS One, 9, 2014, 1, e83875.
4 GENDEP, MARS, STAR*D. Common genetric variation and antidepres­
sant efficacy in major depressive disorder: a meta-analysis of free
Genome-Wide pharmacogenetic studies. Am J Psychiatry, 2013, 170,
2, s. 207–217.
5 Hunter, A. M., et al.: The Antidepressant Treatment Response (ATR)
Index and treatment outcomes in a placebo-controlled trial of fluoxetine. J Clin Neurophysiol, 2011, 28, 5, s. 478–482.
6 Insel, T. R.: The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry, 2014, 171, 4, s. 395–397.
7 Landro, N. I.: Towards personalized treatment of depression: a candidate gene approach. Scand J Psychol, 2014, 55, 3, s. 219–224.
8 Leuchter, A. F., et al.: Biomarkers to predict antidepressant response.
Curr Psychiatry Rep, 2010, 12, s. 553–562.
9 Ozomaro, U., et al.: Personalized medicine in psychiatry: problems
and promises. BMC Medicine, 2013, 11, 132, s. 1–35.
10 Papakostas, G. I., et al.: Effect of adjunctive L-methylfolate 15 mg
among inadequate responders to SSRIs in depressed patiens who
were stratified by biomarker levels and genotypes: results from a randomized clinical trial. J Clin Psychiatry, 2014, 75, 8, s. 855–863.
11 Raboch, J., et al.: Psychiatrie: Doporučené postupy psychiatrické péče
IV. Psychiatrická společnost ČLS JEP, Praha 2014, s. 208.
12 Simon, G. E. – Perlis, R. H.: Personalized medicine for depression: can
we match patiens with treatments? Am J Psychiatry, 2010, 167, 12,
s. 1445–1455.
13 Uher, R., et al.: An inflammatory biomarker as a differential predator
of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry, 2014, doi: 10.1176/appi.ajp.2014.14010094.
14 Zajkowska, Z. E., et al.: Towards a personalized treatment in depres­
sion: ondocannabinoids, inflammation and stress response. Pharmacogenomics, 2014, 15, 5, s. 687–698.
Individualizace farmakologické léčby
v psychiatrii – zaostřeno na schizofrenii
prof. MUDr. Eva Češková, CSc. CEITEC – MU, Psychiatrická klinika FN Brno,
Katedra interních oborů LF Ostravské univerzity v Ostravě, Oddělení psychiatrické FN Ostrava
prof. MUDr. Ladislav Hosák, Ph.D. Psychiatrická klinika LF UK a FN Hradec Králové
1 Wegener, G. – Rujescu, D.: The current development of CNS drug
research. Int J Neuropsychopharmacol, 2013, 16, s. 1687–1693.
2 Češková, E. – Přikryl, R. – Péč, O.: Schizofrenie u dospělých. In: Psychiatrie: Doporučené postupy psychiatrické péče IV. Praha: Psychiatrická
společnost ČLS JEP, 2014, s. 44–51.
3 Hasan, A. – Falkai, P. – Wobrock, T., et al.: World Federation of Socie­
ties of Biological Psychiatry (WFSBP) Guidelines for Biological Treat­
ment of Schizophrenia, part 1: update 2012 on the acute treatment
of schizophrenia and the management of treatment resistance. World
J Biol Psychiatry, 2012, 13, s. 318–378.
4 Hasan, A. – Falkai, P. – Wobrock, T., et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological
treatment of schizophrenia, part 2: update 2012 on the long-term
treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry, 2013, 14, s. 2–44.
5 Larsen, T. M. – Munk-Olsen, T. –Vestergaard, M.: Life expectancy and
cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry, 2012, 25, s. 83–88.
6 Correll, C. U.: From receptor pharmacology to improved outcomes in
individualising the selection, dosing and switching of antipsychotics.
Eur Psychiatry, 2010, dopl. 2, s. 12–21.
7 Mokhtari, M. – Rajarethinam, R.: Early intervention and the treatment
of prodrome in schizophrenia: a review of recent developments. J Psychiatr Pract, 2013, 19, s. 375–385.
8 Češková E.: Schizofrenie a její léčba. 3. vydání. Praha: Maxdorf-Jesse­
nius, 2012, 270.
9 Češková, E.: Schizofrenie. Postgraduální medicína, 2013, 15, s. 90–98.
10 Kishi, T. – Iwata, N.: Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol, 2014, 17, s. 343–354.
11 Michalopoulou, P. G. – Lewis, S. W. – Wykes, T. – Jaeger, J. – Kapur,
S.: Treating impaired cognition in schizophrenia: the case for combining cognitive-enhancing drugs with cognitive remediation. Eur
Neuropsychopharmacol, 2013, 23, s. 790–798.
12 Arranz, M. J. – Rivera, M. – Munro, J. C.: Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs, 2011,
25, s. 933–969.
13 Mas, S. – Lierena, A. – Saiz, J. – Bernardo, M. – Lafuente, A.: Strengths
and weaknesses of pharmacogenetic studies of antipsychotic drugs:
the potential value of the PEPs study. Pharmacogenomics, 2012, 13,
s. 1773–1782.
14 Hiemke, C. – Baumann, P. – Bergmann, N., et al.: AGNP consensus
guideline for therapeutic drug monitoring in psychiatry: update 2011.
Pharmacopsychiatry, 2011, 44, s. 195–235.
ACTA MEDICINAE 11/2014 FARMAKOLOGICKÁ LEČBA Kompletní literatura
Dlouhodobá účinnost glatiramer acetátu
v podmínkách klinické praxe
MUDr. Jiří Slíva, MD., Ph.D. Ústavy farmakologie 2. a 3. LF UK Praha
1 Arnal-García, C. – Amigo-Jorrin, M. D. – López-Real, A. M. – Lema-Devesa, C. – Llopis, N. – Rosa, R. S. – XPERIENCIA-5 Study Group:
Long-term effectiveness of glatiramer acetate in clinical practice
conditions. Journal of Clinical Neuroscience. Publikováno před tiskem
22. 9. 2014, doi: 10.1016/j.jocn.2014.05.045.
2 Cadavid, D. – Wolansky, L. J. – Skurnick, J. – Lincoln, J. – Cheriyan,
J. – Szczepanowski, K. – Kamin, S. S. – Pachner, A. R. – Halper, J. –
Cook, S. D.: Efficacy of treatment of MS with IFNbeta-1b or glatiramer
acetate by monthly brain MRI in the BECOME study. Neurology, 2009,
72, s. 1976–1983.
3 Comi, G. – Filippi, M. – Wolinsky, J. S.: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the
effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple
sclerosis. European/Canadian Glatiramer Acetate Study Group. Annals
of Neurology, 2001, 49, s. 290–297.
4 Johnson, K. P. – Brooks, B. R. – Cohen, J. A. – Ford, C. C. – Goldstein,
J. – Lisak, R. P. – Myers, L. W. – Panitch, H. S. – Rose, J. W. – Schiffer,
R. B.: Copolymer 1 reduces relapse rate and improves disability in
relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple
Sclerosis Study Group. Neurology, 1995, 45, s. 1268–1276.
5 Mikol, D. D. – Barkhof, F. – Chang, P. – Coyle, P. K. – Jeffery, D. R. –
Schwid, S. R. – Stubinski, B. – Uitdehaag, B.: REGARD study group:
Comparison of subcutaneous interferon beta-1a with glatiramer
acetate in patients with relapsing multiple sclerosis (the REbif vs
Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology, 2008,
7, s. 903–914.
6 O’Connor, P. – Filippi, M. – Arnason, B. – Comi, G. – Cook, S. – Goodin, D. – Hartung, H. P. – Jeffery, D. – Kappos, L. – Boateng, F. – Filippov, V. – Groth, M. – Knappertz, V. – Kraus, C. – Sandbrink, R. – Pohl,
C. – Bogumil, T.: 250 microg or 500 microg interferon beta-1b versus
20 mg glatiramer acetate in relapsing-remitting multiple sclerosis:
a prospective, randomised, multicentre study. Lancet Neurology, 2009,
8, s. 889–897.
7 Qizilbash, N. – Mendez, I. – Sanchez-de la Rosa, R.: Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated
syndrome multiple sclerosis. Clinical Therapy, 2012, 34, s. 159–176.
8 Ford, C. – Goodman, A. D. – Johnson, K. – Kachuck, N. – Lindsey, J.
W. – Lisak, R. – Luzzio, C. – Myers, L. – Panitch, H. – Preiningerova,
J. – Pruitt, A. – Rose, J. – Rus, H. – Dolinsky, J.: Continuous long-term
immunomodulatory therapy in relapsing multiple sclerosis: results
from the 15-year analysis of the US prospective open-label study of
glatiramer acetate. Multiple Sclerosis, 2010, 16, s. 342–350.
9 Rovaris, M. – Comi, G. – Rocca, M. A. – Valsasina, P. – Ladkani, D. –
Pie­ri, E. – Weiss, S. – Shifroni, G. – Dolinsky, J. S. – Filippi, M. – European/Canadian Glatiramer Acetate Study Group: Long-term
follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind,
placebo-controlled, MRI-monitored trial. Multiple Sclerosis, 2007, 13,
s. 502–508.
10 Fernandez, O.: Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis. Journal of Central Nervous System Disease, 2012, 4, s. 117–133.
11 Johnson, K. P. – Brooks, B. R. – Ford, C. C. – Goodman A., et al.:
Sustained clinical benefits of glatiramer acetate in relapsing multiple
sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis
Study Group. Multiple Sclerosis, 2000, 6, s. 255–266.
12 Ford, C. C. – Johnson, K. P. – Lisak, R. P. – Panitch, H. S. – Shifronis,
G. – Dolinsky, J. S. – Copaxone Study Group: A prospective open-label study of glatiramer acetate: over a decade of continuous use
in multiple sclerosis patients. Multiple Sclerosis, 2006, 12, s. 309–320.
13 Johnson, K. P. – Ford, C. C. – Lisak, R. P. – Dolinsky, J. S.: Neurologic
consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurologica Scandinavica, 2005, 111, s. 42–47.
14 Debouverie, M. – Moreau, T. – Lebrun, C. – Heinzlef, O. – Brusin, F. –
Msihid, J.: A longitudinal observational study of a cohort of patients
with relapsing-remitting multiple sclerosis treated with glatiramer
acetate. European Journal of Neurology, 2007, 14, s. 1266–1274.
15 Sinic, C. J. – Seeldrayers, P. – Vande Gaer, L. – De Smet, E., et al.:
Long-term follow up of glatiramer acetate compassionate use in Belgium. Acta Neurologica Belgica, 2005, 105, s. 81–85.
16 Miller, A. – Spada, V. – Beerkircher, D. – Kreitman, R. R.: Long-term
(up to 22 years), open-label, compassionate-use study of glatiramer
acetate in relapsing-remitting multiple sclerosis. Multiple Sclerosis,
2008, 14, s. 494–499.
17 Fernández-Fernández, Ó. – Garcia-Trujillo, L. – Guerrero-Fernández,
M., et al.: The effectiveness of glatiramer acetate in clinical practice:
an observational study. Review of Neurology, 2012, 54, s. 1–9.
18 Haas, J. – Firzlaff, M.: Twenty-four-month comparison of immunomodulatory treatments—a retrospective open label study in 308 RRMS
patients treated with beta interferons or glatiramer acetate (Copaxone). European Journal of Neurology, 2005, 12, s. 425–431.
19 Carrá, A. – Onaha, P. – Sinay, V. – Alvarez, F. – Luetic, G. – Bettinelli,
R. – San Pedro, E. – Rodríguez, L.: A retrospective, observational study comparing the four available immunomodulatory treatments for
relapsing-remitting multiple sclerosis. European Journal of Neurology,
2003, 10, s. 671–676.
20 Castelli-Haley, J. – Oleen-Burkey, M. A. – Lage, M. J. – Johnson, K.:
Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat
and persistent-use cohorts. Journal od Medicinal Economy, 2010, 13,
s. 464–471.
21 Lublin, F. D. – Cofield, S. S. – Cutter, G. R. – Conwit, R. – Narayana, P.
A., et al.: CombiRx Investigators: Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology,
2013, 73, s. 327–340.
22 Dolinsky, J. S. – Narayana, P. A. – Johnson, K. P.: United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and
the MRI Analysis Center. Multiple Sclerosis, 2001, 7, s. 33–41.
Nové trendy ve vakcinologii
MUDr. Veronika Horáková Ústav imunologie 2. LF a FN v Motole, Praha
1 Siegrist, C. A.: Vaccines. Elsevier Saunders, 2013, s. 14–32.
2 Plotkin, S. A.: Vaccines: the Fourth Century. Clin Vaccine Immunol,
2009, 16, s. 1709–1719.
3 Ahmad, H. – Chapnick, E. K.: Conjugated polysaccharide vaccines.
Infect Dis Clin N Am, 1999, 13, s. 113–133.
4 Coffman, R. L. – Sher, A. – Seder, R. A.: Vaccine adjuvants: putting
innate immunity to work. Imunity, 2010, 33, s. 492–503.
5 Donati, C. – Rappuoli, R.: Reverse vaccinology in the 21st century:
improvements over the original design. Ann N Y Acad Sci, 2013, 1285,
s. 115–132.
6 Thors, V. S. – Marlow, R. D. – Finn, A.: Current developments and
trends in childhood immunization. Paediatr Child Health, 2013, 23,
s. 103–108.
7 De Gregorio, E. – Tritto, E. – Rappuoli, R.: Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol, 2008, 38, s. 2068–2071.
8 Lambrecht, B. N. – Kool, M. – Willart, M. A., et al.: Mechanism of
action of clinically approved adjuvants. Curr Opin Immunol, 2009, 21,
s. 23–29.
9 Puledran, B. – Hed, R.: Immunological mechanism of vaccination.
Nat Immunol, 2011, 12, s. 509–517.
10 Shoenfeld, Y. – Agmon Levin, N.: ASIA – Autoimmune/inflammatory
syndrome induced by adjuvants. J Autoimmun, 2011, 36, s. 4–8.
11 Israeli, E. – Agmon Levin, N. – Blank, M. – Shoenfeld, Y.: Macrophagic myofasciitis a vaccine (alum) autoimmune related disease. Clin
Rev Allerg Immunol, 2001, 41, s. 163–168.
12 Didierlaurent, A. M. – Morel, S. – Lochman, L., et al.: AS04, an aluminium salt and TLR 4 agonist-based adjuvant system, induces
a tran­sient localized innate immune response leading to enhanced
adaptive immunity. J Immunol, 2009, 183, s. 6186–6197.
13 Belshe, R. B. – Edwards, K. M. – Vesikari, T. – Blafl, V., et al.: Live attenuated versus inactivated influenza vaccine in infants and young chil­
dren. N Engl J Med, 2007, 356, s. 685–696.
14 Laurent, P., et al.: Evaluation of the clinical performance of new intradermal vaccine administration technique and associated delivery
system. Vaccine, 2007, 25, s. 8833–8842.
15 Donnelly, J. – Medini, D. – Boccadifuoco, G., et al.: Qualitative and
quantitative assessment of meningococcal antigens to evaluate the
potential strain coverage of protein-based vaccines. Proc Natl Acad
Sci USA, 2010, 107, s. 19490–19495.
16 Křížová, P. – Musílek, M. – Vacková, Z., et al.: Invazivní meningokokové onemocnění v České republice v roce 2011. Zprávy centra epidemiologie a mikrobiologie, 2012, 21, s. 106–111.
17 Markowitz, L. E. – Hariri, S., et al.: Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine
introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis, 2013, 208, s. 385–393.
18 Plotkin, S. A.: Vaccines, Vaccination, and Vaccinology. J Infect Dis, 2003,
187, s. 1349–1359.
Avanafil – nová možnost volby v léčbě erektilní dysfunkce
MUDr. Lukáš Bittner, FEBU, FECSM Urologická klinika 3. LF UK a FNKV
1 Weiss, P. – Zvěřina, J.: Sexuální chování v ČR. 1993, 1998, 2003, 2008.
2 Porst, H.: Use of avanafil and successful intercourse within approximately 15 minutes of dosing in men with mild to severe erectile dysfunction. European Urology, Supplements, 2014, 13, s. e600–e600a.
3 Goldstein, I. – McCullough, A. R. – Jones, L. A. – Hellstrom, W. J. –
Bowden, C. H., et al.: A randomized, double-blind, placebo-control­
led evaluation of the safety and efficacy of avanafil in subjects with
erectile dysfunction. J Sex Med, 2012, 9, s. 1122–1133.
4 Wang, R. – Burnett, A. L. – Heller, W. H., et al.: Selectivity of avanafil,
a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med, 2012, 9,
s. 2122–2129.
5 Katz, E. G. – Tan, R. B. – Rittenberg, D., et al.: Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and
clinical utility. Ther Clin Risk Manag, 2014, 10, s. 701–711.
6 Cui, Y. S. – Li, N. – Zong, H. T. – Yan, H. L. – Zhang, Y.: Avanafil for male
erectile dysfunction: a systematic review and meta-analysis. Asian
J Androl, 2014, 16, s. 472–477.
7 Goldstein, I. – Jones, L. A. – Belkoff, L. H., et al.: Avanafil for the
treat­ment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clin Proc, 2012,
87, s. 843–852.
ACTA MEDICINAE 11/2014 FARMAKOLOGICKÁ LEČBA Kompletní literatura